What CAD is—and what it is not
What is cold agglutinin disease?
Cold agglutinin disease (CAD) is a clonal, complement-mediated hemolytic disorder in which a pathogenic IgM autoantibody binds red blood cells at lower temperatures and activates the classical complement pathway, leading predominantly to C3-mediated extravascular hemolysis.1
Conceptual anchor:
The antibody initiates. Complement determines the phenotype.
Key defining elements
- a monoclonal IgM autoantibody, usually κ-restricted2
- classical complement activation as the dominant effector mechanism3
- C3 deposition on red blood cells4
- hepatic clearance rather than splenic destruction, reflecting Kupffer-cell recognition of complement-opsonized erythrocytes5
- chronic or relapsing disease course in most primary cases6
CAD is not simply “autoimmune hemolytic anemia triggered by cold.” It is a mechanistically distinct entity with its own biology, kinetics, and therapeutic vulnerabilities.7
What is a cold agglutinin?
A cold agglutinin is an antibody that binds red blood cell antigens more avidly at temperatures below core body temperature.8
Core features:
- most pathogenic cold agglutinins are IgM (Swiecicki PL. Cold agglutinin disease. Blood. 2013.)9
- binding typically occurs in cooler peripheral circulation10
- dissociation often occurs on rewarming11
- complement activation may persist after antibody disengagement12
This temporal uncoupling explains why hemolysis may continue even after red cells return to warmer central circulation.
Cold agglutinins are common in human sera. Cold agglutinin disease is not.13
Cold agglutinins versus cold agglutinin disease
The presence of a cold agglutinin does not equal CAD.14
Important distinctions:
Transient cold agglutinins15
- often polyclonal
- commonly post-infectious
- usually self-limited
- may cause mild or no hemolysis
Cold agglutinin disease16
- typically monoclonal
- persistent
- complement-driven hemolysis
- usually associated with a clonal bone marrow disorder
Why clonality matters:17
Clonality implies a persistent antibody source, which explains why primary CAD is chronic rather than self-limited.
Failure to separate transient polyclonal cold agglutinins from clonal monoclonal disease has historically led to diagnostic confusion and inappropriate therapy.
Primary CAD versus secondary cold agglutinin syndromes
Primary CAD18
- chronic clonal disorder
- IgM produced by an indolent B-cell clone
- complement-mediated hemolysis intrinsic to disease
Secondary cold agglutinin syndromes
occur in association with:19
- acute infections
- autoimmune diseases
- overt lymphoid malignancies
In secondary syndromes, treatment targets the underlying condition. In primary CAD, therapy must address complement activation or the clonal source.
This distinction materially changes prognosis, monitoring strategy, and treatment selection.20
Thermal amplitude
Thermal amplitude is the highest temperature at which a cold agglutinin binds red blood cells.21
Why it matters22
- higher thermal amplitude → greater physiologic relevance
- predicts clinical impact better than titer alone
- explains severe disease despite modest antibody levels
Antibodies capable of binding at near-core temperatures interact with erythrocytes in central circulation, not just acral regions, which explains disproportionate disease severity. This explains why an antibody that binds at 30 °C is clinically dangerous while one that binds only at 4 °C may be biologically irrelevant.
Complement as the central effector
In CAD:23
- the antibody initiates the process
- complement determines the phenotype
Key principles24
- hemolysis is classical pathway dependent
- C3 deposition is dominant
- most destruction is extravascular
- terminal complement lysis is usually limited
Limited terminal pathway activation helps explain why CAD typically presents with chronic anemia rather than fulminant intravascular hemolysis. Host complement regulators on the red-cell surface restrict progression to full membrane-attack–complex formation.
This mechanism also explains therapeutic logic: proximal complement blockade can suppress hemolysis without eliminating the pathogenic clone.25
Clonality and bone marrow involvement
Most patients with primary CAD have:26
- a detectable monoclonal IgM
- an underlying indolent B-cell lymphoproliferative disorder
- disease largely confined to bone marrow
CAD is therefore best understood as a clonal marrow disorder with immune manifestations, not a purely reactive autoimmune condition.27
The precise classification of the underlying clone has evolved historically, underscoring that disease definitions reflect current biologic understanding rather than fixed categories.
Common clinical misconceptions
CAD is not:28
- primarily IgG mediated
- predominantly splenic in clearance
- reliably steroid responsive
- defined by antibody titer alone
- a uniform or predictable disease
Steroid responsiveness is the exception, not the rule.
Misunderstanding what CAD is not has historically driven ineffective therapy.
Core conceptual summary
Cold agglutinin disease rests on three biologic pillars:
- clonality determines persistence
- complement determines phenotype
- thermal amplitude determines pathogenicity
CAD is therefore a complement disease before it is a hemolytic one.
Its mechanism is defined.
Its expression is variable.
Its classification is useful but not absolute.
Effective care depends on knowing which features are definitional, which are variable, and which only appear important.
Test your thinking
Test your ability to distinguish definitions, mechanisms, and diagnostic criteria in cold agglutinin disease.
Guideline perspective
How consensus documents define and diagnose cold agglutinin disease
Diagnostic definition (international consensus)
Primary CAD is defined by chronic hemolysis, a cold agglutinin titer typically ≥64 at 4 °C, characteristic direct antiglobulin test findings, and absence of an underlying associated disorder.29
DAT profile
The typical serologic pattern is a monospecific DAT strongly positive for C3d alone, with IgG usually negative but weakly positive in up to 20% of patients.30
Titer interpretation
Titer should be reported as the reciprocal of the highest dilution producing agglutination, recognizing that rare cases of clinically significant CAD may occur with titers below 64.31
Thermal amplitude testing
Measurement of thermal amplitude is not required for diagnosis in most patients but may be useful in selected cases to distinguish pathologic antibodies from benign low-titer cold agglutinins.32
Primary vs secondary disease
The same laboratory criteria apply to secondary cold agglutinin syndrome, and clinical, histologic, and radiologic evaluation should be performed to exclude underlying malignancy or other causes.33
Underlying clonal disorder
Serum monoclonal IgMκ is detectable in >90% of patients, and clonal B-cells are usually demonstrable in marrow using sensitive methods.34